Brief: Theranexus Initiates Recruitment For Phase I/II Study In Batten Disease With BBDF

Thx Pharma SA

03/02/2022 17:13

Feb 3 (Reuters) - Theranexus SA  ALTHX.PA :
    * INITIATE WITH THE BBDF THE RECRUITMENT FOR PHASE I/II
STUDY IN
BATTEN DISEASE
    * THE RESULTS OF THIS TITRATION PHASE WILL BE AVAILABLE AT
THE
BEGINNING OF THE SECOND HALF OF 2022
    * PLANS, AFTER CONSULTATION WITH THE FDA, TO INITIATE A
PIVOTAL
PHASE III STUDY IN LATE 2022 STUDY AT THE END OF 2022
    * THIS STUDY  WILL INCLUDE A PAEDIATRIC COHORT OF 30
PATIENTS WITH
PATIENTS WITH REGULAR MEASUREMENTS TO ASSESS DISEASE PROGRESSION
AND SAFETY

Source text for Eikon:  ID:nACT73085 
Further company coverage:  ALTHX.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))